Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Human skeletal myopathy myosin mutations disrupt myosin head sequestration
Glenn Carrington, … , Michelle Peckham, Julien Ochala
Glenn Carrington, … , Michelle Peckham, Julien Ochala
Published October 3, 2023
Citation Information: JCI Insight. 2023;8(21):e172322. https://doi.org/10.1172/jci.insight.172322.
View: Text | PDF
Research Article Muscle biology

Human skeletal myopathy myosin mutations disrupt myosin head sequestration

  • Text
  • PDF
Abstract

Myosin heavy chains encoded by MYH7 and MYH2 are abundant in human skeletal muscle and important for muscle contraction. However, it is unclear how mutations in these genes disrupt myosin structure and function leading to skeletal muscle myopathies termed myosinopathies. Here, we used multiple approaches to analyze the effects of common MYH7 and MYH2 mutations in the light meromyosin (LMM) region of myosin. Analyses of expressed and purified MYH7 and MYH2 LMM mutant proteins combined with in silico modeling showed that myosin coiled coil structure and packing of filaments in vitro are commonly disrupted. Using muscle biopsies from patients and fluorescent ATP analog chase protocols to estimate the proportion of myosin heads that were super-relaxed, together with x-ray diffraction measurements to estimate myosin head order, we found that basal myosin ATP consumption was increased and the myosin super-relaxed state was decreased in vivo. In addition, myofiber mechanics experiments to investigate contractile function showed that myofiber contractility was not affected. These findings indicate that the structural remodeling associated with LMM mutations induces a pathogenic state in which formation of shutdown heads is impaired, thus increasing myosin head ATP demand in the filaments, rather than affecting contractility. These key findings will help design future therapies for myosinopathies.

Authors

Glenn Carrington, Abbi Hau, Sarah Kosta, Hannah F. Dugdale, Francesco Muntoni, Adele D’Amico, Peter Van den Bergh, Norma B. Romero, Edoardo Malfatti, Juan Jesus Vilchez, Anders Oldfors, Sander Pajusalu, Katrin Õunap, Marta Giralt-Pujol, Edmar Zanoteli, Kenneth S. Campbell, Hiroyuki Iwamoto, Michelle Peckham, Julien Ochala

×

Figure 1

Myosinopathies and location of mutations.

Options: View larger image (or click on image) Download as PowerPoint
Myosinopathies and location of mutations.
(A) A schematic showing the ov...
(A) A schematic showing the overall composition of striated myosin. The molecule is formed by 2 heavy chains that dimerize to form a coiled coil tail composed of subfragment-2 (S-2) and light-meromyosin (LMM). The 2 heavy chains diverge to form the neck of lever, to which light chains bind, and the 2 motor domains, which bind actin and nucleotide. (B) A schematic showing an end on view of the heptad repeat of 2 interacting α-helices. Residues in “a” and “d” positions form the hydrophobic seam. (C) The frequency of mutations in MYH7 for hypertrophic cardiomyopathy (HCM) (gray dotted line) and for skeletal myopathies (myosinopathy, green line), across the amino acid sequence of MYH7. (D) The sequence in which mutations that cause myosinopathies are most frequent. Positions of mutations (commonly mutation to proline or a single amino acid deletion) are indicated by colored arrows. Mutations in residues mutated in HCM are indicated by an asterisk. Underlined residues indicate the position of mutated residues studied here. The heptad repeat is shown underneath the sequence, with “d” positions highlighted in magenta.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts